Literature DB >> 12589835

Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south India.

Sukanya Raghuraman1, R V Shaji, Gopalan Sridharan, Sujatha Radhakrishnan, George Chandy, B S Ramakrishna, Priya Abraham.   

Abstract

BACKGROUND: Genotyping of the hepatitis C virus (HCV) and assessment of viral load is important for designing therapeutic strategies and region specific diagnostic assays.
OBJECTIVES: To determine the distribution of HCV genotypes among patients attending a tertiary care hospital in south India, and to correlate this with viral load. STUDY
DESIGN: Ninety HCV RNA positive patients were recruited for the study. HCV genotyping was carried out using type-specific primers from the core region of the viral genome [J. Clin. Microbiol. 35 (1997) 201]. Viral load estimations were carried out using the Amplicor HCV Monitor (Versions 1.5 and 2, Roche Diagnostics, Branchburg, NJ, USA). Clinical details were elicited from patients' hospital records.
RESULTS: Genotype 3 was detected most frequently (62.2%) followed by infection with HCV genotype 1 (18.8%). There was no significant difference seen in alanine aminotransferase (ALT) values between the two genotypes. Genotype 1 was associated with a significantly higher viral load as compared with genotype 3 (P=0.001). Parenteral transmission accounted for 61% of all infection caused. Infection with genotype 1 was significantly associated with a history of haemodialysis (P=0.01). Genotype 3 was detected more frequently in patients from east India, as compared with its detection in patients from south India (P=0.004). Similarly, genotype 1 was detected with greater frequency in individuals from south India as compared with patients from east India (P=0.004). The concordance between Ohno's genotyping assay and nucleotide sequencing, for genotypes 1 and 3, was 75%.
CONCLUSIONS: HCV genotypes 1 and 3 accounted for 81% of HCV infections in patients from this geographical region. HCV genotype distribution showed regional differences and genotype 1 was associated with higher viral loads. Parenteral transmission was the major route for acquisition of HCV infection. Ohno's type-specific primer based genotyping assay can be used for distinguishing between HCV genotype 1 and non-1 HCV genotypes in laboratories that do not possess nucleotide sequencing facilities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12589835     DOI: 10.1016/s1386-6532(02)00025-2

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  18 in total

1.  Evaluation of a rapid assay as an alternative to conventional enzyme immunoassays for detection of hepatitis C virus-specific antibodies.

Authors:  Hubert Darius J Daniel; Priya Abraham; Sukanya Raghuraman; Perumal Vivekanandan; Thenmozhi Subramaniam; Gopalan Sridharan
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

Review 2.  Hepatitis C in India.

Authors:  Ashis Mukhopadhyaya
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

3.  Comparison of 5' noncoding-core with 5' noncoding regions of HCV by RT-PCR: importance and clinical implications.

Authors:  Vikas Verma; Anita Chakravarti
Journal:  Curr Microbiol       Date:  2008-07-09       Impact factor: 2.188

Review 4.  Tackling the Hepatitis C Disease Burden in Punjab, India.

Authors:  Radha K Dhiman; Sandeep Satsangi; Gagandeep S Grover; Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2016-09-07

5.  Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin-A Multicenter Study.

Authors:  Subrat K Acharya; V Sreenivas; Siddharth Datta Gupta; Shakti Kumar; Yogesh K Chawla; Anurag Tandon; Aejaz Habeeb; Premashish Kar; Abhijit Chowdhury; Gourdas Choudhuri; Shiv K Sarin; Dn Amarapurkar; Vidya Arankalle; Mohan D Gupte; Sushma Gupta; Deepali Mukherjee; Divya Seth; Rohit Goyal; Badri N Tandon
Journal:  J Clin Exp Hepatol       Date:  2012-04-12

6.  Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India.

Authors:  Vinod K Dixit; Jayanta K Ghosh; Sangey C Lamtha; Pankaj Kaushik; Sundeep K Goyal; Manas K Behera; Neha Singh; Ashok K Jain
Journal:  J Clin Exp Hepatol       Date:  2014-06-18

Review 7.  Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part I: Status Report of HCV Infection in India.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Radha K Dhiman; Rakesh Aggarwal; Shivram P Singh; Deepak Amarapurkar; Anil Arora; Mohinish Chhabra; Kamal Chetri; Gourdas Choudhuri; Vinod K Dixit; Ajay Duseja; Ajay K Jain; Dharmesh Kapoorz; Premashis Kar; Abraham Koshy; Ashish Kumar; Kaushal Madan; Sri P Misra; Mohan V G Prasad; Aabha Nagral; Amarendra S Puri; R Jeyamani; Sanjiv Saigal; Shiv K Sarin; Samir Shah; P K Sharma; Ajit Sood; Sandeep Thareja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2014-06-09

8.  Early Experience of Sofosbuvir based Combination Therapy in "Real-Life" Cohort with Chronic Hepatitis-C Infection.

Authors:  Rajiv Mehta; Mayank Kabrawala; Subhash Nandwani; Rini Tekriwal; Payal Nandania
Journal:  J Clin Diagn Res       Date:  2017-03-01

9.  Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease.

Authors:  Rachel Abraham; Banumathi Ramakrishna; Avinash Balekuduru; Hubert Darius J Daniel; Priya Abraham; C Eapen Eapen; George Kurian
Journal:  Indian J Gastroenterol       Date:  2009-08-21

10.  Comparison of Three Different Hepatitis C Virus Genotyping Methods: 5'NCR PCR-RFLP, Core Type-Specific PCR, and NS5b Sequencing in a Tertiary Care Hospital in South India.

Authors:  Hubert D-J Daniel; Joel David; Sukanya Raghuraman; Manu Gnanamony; George M Chandy; Gopalan Sridharan; Priya Abraham
Journal:  J Clin Lab Anal       Date:  2016-09-01       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.